AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03774537
Drug: Transplantation of hUC-MSCs
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs through intravenous infusion. Dose A - 1 million cells per kg; Dose B - 5 million cells per kg
Trial: NCT03774537
Drug: No transplantation of hUC-MSCs
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs
Trial: NCT03444883
Drug: Ilaprazole
RxNorm normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mgx2 tablet once daily for weeks
Trial: NCT05589753
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 6 days. On the final 4 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
Trial: NCT02331511
Drug: Aspirin 80 mg daily
RxNorm normalized name: aspirin 80 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 80 mg daily administration for 3 months after device(PPM,ICD,CRT) implantation
Trial: NCT02331511
Drug: Clopidogrel 75 mg daily
RxNorm normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel administration for 3 months after device(PPM,ICD,CRT) implantation
Trial: NCT00004933
Drug: hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 to 5 grams PO per day
Trial: NCT00004933
Drug: Homoharringtonine
RxNorm normalized name: Homoharringtonine
DrugBank: Omacetaxine mepesuccinate (DB04865)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg/ sq m/ day CIVI for 14 days
Trial: NCT01430533
Drug: azelaic acid pre foam formulation
RxNorm normalized name: azelaic acid Topical Foam
DrugBank: Azelaic acid (DB00548)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01430533
Drug: Water
RxNorm normalized name: Water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02890329
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02420353
Drug: Somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GH dose will be calculated by nomogram estimation of body surface area, and will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin GH treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take GH, but otherwise patients will take GH every day over this 6 week period.
Trial: NCT01293097
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
Trial: NCT04138251
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral administration of Empagliflozin
Trial: NCT01159145
Drug: D961H
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral, capsule
Trial: NCT01159145
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, tablet
Trial: NCT03169816
Drug: Lorcaserin
RxNorm normalized name: Lorcaserin
DrugBank: Lorcaserin (DB04871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lorcaserin 10mg, twice daily
Trial: NCT00930215
Drug: D961H
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral gelatin capsule
Trial: NCT00930215
Drug: D961H
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral HPMC capsule
Trial: NCT01149057
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 mg/kg intravenously, every 4 weeks for 96 weeks
Trial: NCT03905967
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients \<60kg, and 12 mg qd for patients \>60kg)
Trial: NCT03602339
Drug: Gadoterate (Dotarem/Clariscan)
RxNorm normalized name: GADOTERATE
DrugBank: Gadoteric acid (DB09132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received a single dose of 0.5 molar gadoterate (0.1 mmol per kg body weight) intravenously.
Trial: NCT03602339
Drug: Gadobutrol (Gadavist/Gadovist, BAY86-4875)
RxNorm normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received a single dose of 1.0 molar BAY86-4875 (0.075 mmol per kg body weight) intravenously.
Trial: NCT01140672
Drug: PF-04634817
RxNorm normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
Trial: NCT03630627
Drug: SB26
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SB26 administered intravenously
Trial: NCT02206568
Drug: URAL
RxNorm normalized name: Curaler
DrugBank: Nitrofural (DB00336)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01652898
Drug: ONO LDL50
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 3 different doses ONO LDL50, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
Trial: NCT01652898
Drug: Esmolol hydrochloride
RxNorm normalized name: Esmolol Hydrochloride
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of 3 different doses Esmolol, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
Trial: NCT04275115
Drug: Foliglurax
RxNorm normalized name: Foliglurax
DrugBank: Foliglurax (DB15292)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foliglurax
Trial: NCT04275115
Drug: midazolam iv
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single intravenous (iv) dose of midazolam 0.025 mg/kg
Trial: NCT00955994
Drug: asimadoline
RxNorm normalized name: Asimadoline
DrugBank: Asimadoline (DB05104)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01140672
Drug: PF-04634817
RxNorm normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution of PF-04634817 at 30 mg will be given once daily for 14 days.
Trial: NCT01140672
Drug: PF-04634817
RxNorm normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution of PF-04634817 at 100 mg will be given once daily for 14 days.
Trial: NCT01140672
Drug: PF-04634817
RxNorm normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution of PF-04634817 at 300 mg will be given once daily for 14 days.
Trial: NCT01140672
Drug: PF-04634817
RxNorm normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort will only be dosed if necessary. Dose selected for this cohort may be a repeat of a previous cohort or intermediate dose not to exceed 300 mg.
Trial: NCT02761915
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02294305
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01868243
Drug: Dabigatran
RxNorm normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 - Dabigatran 110 mg (50 patients)
Trial: NCT01868243
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin adjusted-dose
Trial: NCT03354338
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Periodontal treatment; Pre-medication with 2 gr of oral Amoxicillin 1 hour before treatment
Trial: NCT02824510
Drug: Insulin aspart, glargine and detemir
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02775994
Drug: Canakinumab
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: interleukin beta (IL-1) antagonist
Trial: NCT02957877
Drug: Nadroparin
RxNorm normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A nadroparin infusion regimen (loading dose of 35 IU/kg, followed by 10 IU/kg per hour for 6 hours) is administered as anticoagulation during the 8-hour hemodialysis.
Trial: NCT02899156
Drug: Flumazenil
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01874535
Drug: Esomeprazole 40 mg
RxNorm normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
Trial: NCT03961360
Drug: Aspirin 81 mg
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia
Trial: NCT03573544
Drug: OBI-888
RxNorm normalized name: OBI-888
DrugBank: OBI-888 (DB18289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the dose-escalation phase, OBI-888 will be given weekly at the dose levels of 5, 10, and 20 mg/kg.
Trial: NCT03573544
Drug: OBI-888
RxNorm normalized name: OBI-888
DrugBank: OBI-888 (DB18289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the dose-expansion phase, OBI-888 will be given weekly at 20 mg/kg dose level.
Trial: NCT00096655
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04371224
Drug: Irinotecan Liposomal Injection [Onivyde]
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: both arm
Trial: NCT04371224
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NAPOLI
Trial: NCT02957877
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The individualized unfractionated heparin infusion regimen currently employed by the recruited patients in their home dialysis treatment is administered as anticoagulation during the 8-hour hemodialysis.
Trial: NCT00227370
Drug: valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: valgan 900mg QD x 9 months post lung transplant
Trial: NCT00983996
Drug: Alendronate Sodium Tablets, 10 mg
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg, single-dose fasting
Trial: NCT03961360
Drug: Aspirin 162 mg
RxNorm normalized name: aspirin 162 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia
Trial: NCT01493180
Drug: Sodium hyaluronate ophthalmic solution
RxNorm normalized name: sodium hyaluronate Ophthalmic Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate ophthalmic solution 0.1%
Trial: NCT00218465
Drug: GW468816
DrugBank: GW 468816 (DB05417)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapies for Relapse Prevention
Trial: NCT04241965
Drug: OPC-214870
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s)
Trial: NCT03051945
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug will be infused while the participant sits or lies in a comfortable position. The dose of ketamine used does not cause unconsciousness but may cause perceptual disturbances.
Trial: NCT02674529
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selective Serotonin Reuptake Inhibitor (SSRI)
Trial: NCT02891850
Drug: Riociguat (Adempas, BAY63-2521)
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film-coated tablets will be used in this study at a dosage of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg. Tablets will be administered orally.The starting dose is 1 mg TID; the intervals between drug intakes should be 6 to 8 hours. The dosage should be increased by 0.5 mg increments in 2 week intervals to 1.5 mg, 2.0 mg, and 2.5 mg TID (maximal total daily dose).
Trial: NCT02891850
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
Trial: NCT02891850
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
Trial: NCT03566394
Drug: Gabapentin 300mg
RxNorm normalized name: GABAPENTIN 300MG CAP
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 300mg orally three times a day, from 2 days before to 5 days after taxane infusion
Trial: NCT01821521
Drug: AGSPT_L20
RxNorm normalized name: OCTINOXATE 7.5 g in 100 g / TITANIUM DIOXIDE 5.02 g in 100 g TOPICAL LIQUID [Sheer Defense Tinted Moisturizer SPF15 L20 Merle Norman]
DrugBank: Octinoxate (DB09496)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01821521
Drug: Pantoloc 40mg
RxNorm normalized name: Pantol
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00963196
Drug: Bovine gelatin capsules
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine gelatin capsules that appear similar to active drug acting as placebo.
Trial: NCT03506178
Drug: Oxymetazoline Nasal Spray
RxNorm normalized name: oxymetazoline Nasal Spray
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
Trial: NCT03506178
Drug: Menthol Nasal Spray
RxNorm normalized name: PHENYLEPHRINE 0.5%/MENTHOL NASAL SPRAY
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
Trial: NCT01261767
Drug: anti-IL-20
RxNorm normalized name: Anti-IL-20
DrugBank: Fletikumab (DB12356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-IL-20 in 100mg/vial for subcutaneous (under the skin) injection
Trial: NCT02397278
Drug: Platelet rich plasma (PRP)
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will receive 3 intra articular injections with autologous PRP in the affected knee and then follow conventional therapy.
Trial: NCT03759704
Drug: Hyperpolarized 13CPyruvate
RxNorm normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of study drug during MRSI.
Trial: NCT01693653
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusions every 4 weeks for 3 doses.
Trial: NCT01244724
Drug: Lexapro
RxNorm normalized name: Lexapro
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram will begin at 10mg. a day. Visits will occur biweekly for 12 weeks. Subjects with minimal or no response and minimal or no side effects after 4 weeks will have the dose increased to 20mg. a day. The maximum dose of escitalopram will not exceed the FDA-approved maximum dose of 20 mg per day.
Trial: NCT02050529
Drug: Labetalol
RxNorm normalized name: Labetalol
DrugBank: Labetalol (DB00598)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A( Labetalol) will be receive intravenous labetalol bolus doses as specified in protocol summary.
Trial: NCT02050529
Drug: Hydralazine
RxNorm normalized name: Hydralazine
DrugBank: Hydralazine (DB01275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group B(Hydralazine) will serve as control and will receive active comparator Hydralazine intravenous bolus doses as specified in summary.
Trial: NCT02638545
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sedation with propofol and remifentanyl will be replaced by a sedation with dexmedetomidine and remifentanyl
Trial: NCT02721563
Drug: Sodium Glycididazole
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Glycididazole 700mg/m2.Three times a week (once every other one day),before radiation therapy, total 6 weeks.
Trial: NCT01120028
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart
Trial: NCT01120028
Drug: Basiliximab
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20 mg intravenously, two doses 96 hours apart
Trial: NCT01120028
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus: target trough levels 6-12 ng/mL for first 6-months after maintenance therapy randomization, then 5-10 ng/mL
Trial: NCT01120028
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus: target trough levels 5-7 ng/mL after maintenance therapy randomization.
Trial: NCT03694535
Drug: bladder wall thermotherapy with Mitomycin-c
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: application of intravesical mitomycin-C with hyperthermia
Trial: NCT02291796
Drug: Bezafibrate
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with ST elevation acute myocardial infarction (STEAMI) and with fibrinogen concentration \>500 mg/dl at 72 h of evolution, were randomly assigned to bezafibrate 400 mg/day or just conventional therapy
Trial: NCT03033433
Drug: DCB-DM101
RxNorm normalized name: DCB
DrugBank: Dichlorobenzene (DB14046)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: determination of optimal dose for Stage 2
Trial: NCT01502904
Drug: pitavastatin 2mg/day after DES implantation
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
Trial: NCT01653041
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00654498
Drug: Pramipexole
RxNorm normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04062175
Drug: cephalosporin
RxNorm normalized name: Cephalosporin
DrugBank: Cephalosporin analog (DB02136)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 72 women will receive single antibiotic chemotherapy(Cefazolin) 2 gm iv within 30 minutes before skin incision
Trial: NCT02531906
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02531906
Drug: Methadone Hydrochloride
RxNorm normalized name: Methadone Hydrochloride
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02531906
Drug: Oxycodone Hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01401062
Drug: Fresolimumab
RxNorm normalized name: Fresolimumab
DrugBank: Fresolimumab (DB12396)
FDA approved: no
EMA approved: no
PMDA approved: no